Sorafenib is a multi-kinase inhibitor that inhibits multiple intracellular and cell surface kinases, including RAF kinase, vascular endothelial growth factor receptor-2 (VEGFR-2), vascular endothelial growth factor receptor-3 (VEGFR-3), platelet-derived growth factor receptor-β (PDGFR -β), KIT and FLT-3. Sorafenib has dual anti-tumor effects, on the one hand, it can directly inhibit tumor growth by inhibiting the RAF/MEK/ERK signaling pathway; on the other hand, it can indirectly inhibit tumor cell growth by blocking the formation of tumor neovascularization through inhibition of VEGFR and PDGFR. As the only targeted drug approved for the treatment of liver cancer, sorafenib has shown good efficacy and safety in several studies. Currently, sorafenib is mainly used as monotherapy or combined with TACE treatment for intermediate to advanced hepatocellular carcinoma lost to surgery, treatment of postoperative recurrence, and also many doctors recommend sorafenib for prophylactic treatment after hepatectomy. The use of sorafenib after resection for non-radical hepatocellular carcinoma has been accepted by most physicians, but there is some controversy as to whether sorafenib after radical resection provides benefit to patients. Common adverse events associated with sorafenib include rash, diarrhea, increased blood pressure, and redness, pain, swelling, or blistering on the palms of the hands or soles of the feet. In clinical trials, the most common treatment-related adverse events were diarrhea, rash/desquamation, fatigue, skin reactions on the hands and feet, hair loss, nausea, vomiting, pruritus, hypertension, and loss of appetite. The number of grade 3 and 4 adverse events accounted for 31% and 7% of the total adverse events in sorafenib-treated patients, respectively, compared with 22% and 6% in placebo-controlled patients. The most common adverse reactions that led to dose reduction or discontinuation of the drug in patients were gastrointestinal reactions, skin reactions, and hepatic dysfunction.